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Abstract
Background: Inflammatory signaling elicited by prolonged seizures can be contributory to neuronal injury as well
as adverse plasticity leading to the development of spontaneous recurrent seizures (epilepsy) and associated
co-morbidities. In this study, developing rat pups were subjected to lithium-pilocarpine status epilepticus (SE) at
2 and 3 weeks of age to study the effect of anti-inflammatory drugs (AID) on SE-induced hippocampal injury and
the development of spontaneous seizures.
Findings: We selected AIDs directed against interleukin-1 receptors (IL-1ra), a cyclooxygenase-2 (COX-2) inhibitor
(CAY 10404), and an antagonist of microglia activation of caspase-1 (minocycline). Acute injury after SE was studied
in the 2-week-old rats 24 h after SE. Development of recurrent spontaneous seizures was studied in 3-week-old rats
subjected to SE 4 months after the initial insult.
None of those AIDs were effective in attenuating CA1 injury in the 2-week-old pups or in limiting the development
of spontaneous seizures in 3-week-old pups when administered individually. When empiric binary combinations of
these drugs were tried, the combined targeting of IL-1r and COX-2 resulted in attenuation of acute CA1 injury, as
determined 24 h after SE, in those animals. The same combination administered for 10 days following SE in 3-week
-old rats, reduced the development of spontaneous recurrent seizures and limited the extent of mossy fiber
sprouting.
Conclusions: Deployment of an empirically designed ‘drug cocktail’ targeting multiple inflammatory signaling
pathways for a limited duration after an initial insult like SE may provide a practical approach to neuroprotection
and anti-epileptogenic therapy.
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Findings
Epilepsy affects approximately 1% of the population. The
principal manifestations of the disease (seizures) as well
as the associated co-morbidities exert a considerable toll
on persons afflicted with this disorder. Despite treatment
with anticonvulsant medications aimed at a number of
pharmacological targets, approximately one-third of
patients remain treatment-resistant [1]. Thus one of the
most important benchmarks for epilepsy research agreed
upon has been therapy to prevent the development of
epilepsy, or anti-epileptogenesis [2].
At the present time no evidence-based treatment for the
prevention of epilepsy and the associated co-morbidities
exists. Clinical trials to address the prevention of post-
traumatic epilepsy have mainly involved a number of anti-
epileptic drugs (AED) and the results have been uniformly
disappointing [3]. In the laboratory setting, a number of
pharmacological and electrical methods can be employed
to produce status epilepticus (SE), which produce
hippocampal injury acutely, while spontaneous recurrent
seizures (SRS) and neurocognitive and behavioral deficits
develop as chronic sequelae. Treatment of experimental
animals with AEDs chronically after a bout of SE has
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resulted in variable degrees of neuroprotection but has
not produced discernible anti-epileptogenic effects [4-7].
A recent review summarizes data suggesting the potential
for achieving anti-epileptogenesis by modulating inflam-
mation after an initial insult such as SE [8]. A large body
of data exists identifying a number of inflammation-
associated mechanisms in mediating neuronal injury. We
hypothesized that multiple pathways are activated after an
insult, and that combination therapy leveraging more than
one target may prove more efficacious in achieving neuro-
protection and in modifying epileptogenesis.
Chronic post-SE animals with SRS (epileptic animals)
demonstrate anatomical and electrophysiological evi-
dence of a form of synaptic plasticity known as mossy
fiber sprouting [9]. Mossy fibers are axons of the dentate
granule cells which make synaptic contacts with the
dendrites of the CA3 pyramidal cells and interneurons
in the hilus which participate in feedback as well as
feed-forward inhibition. In epileptic brains, which dem-
onstrate loss of mossy fiber targets, these axons form re-
current connections to granule cell dendrites in the
inner molecular layer of the dentate gyrus. This form of
synaptic plasticity has been demonstrated in experimen-
tal models of limbic epilepsy as well as surgically
resected hippocampi from humans as a treatment for
medication-resistant temporal lobe epilepsy (TLE). The
extent of sprouting does not appear to correlate with
seizure density [10], while histological data suggest that
the robustness of mossy fiber sprouting may reflect the
extent of hippocampal injury [11].
Here, we report on the effect of an empirically derived
combination therapy directed against inflammatory sig-
naling pathways for a limited duration to achieve dis-
cernible neuroprotection, decrease in SRS, and mossy
fiber sprouting in developing animals. Previous work in
our laboratory established that 2-week-old rat pups
respond with extensive CA1 injury with minimal accom-
panying hilar injury after SE induced by lithium-
pilocarpine treatment [12]. Profound hilar injury is
encountered in 3-week-old pups after SE and these
animals are highly likely to develop SRS and their hippo-
campi demonstrate dense mossy fiber sprouting [12,13].
All experiments were performed in accordance with the
policies of the National Institutes of Health. In order to
study the effect of treatment acute on neuronal injury, we
selected 2-week-old (postnatal day 14, P14) Wistar rat
pups, which showed highly selective CA1 injury which
was enhanced by inflammation induced with lipopolysac-
charide (LPS) pretreatment [14]. Treatment with LPS
enhanced kindling epileptogenesis at this age and animals
followed for 3 months after lithium pilocarpine SE
demonstrated more gliosis and a more severe epileptic
phenotype [15]. In these experiments, rats were injected
with lithium chloride (3 mEq/kg, i.p., given 16 to 18 h
prior to s.c. injection of 60 mg/kg of pilocarpine) as
described before [12-15]. In addition, these animals
received 50 μg/kg of LPS i.p., immediately followed by
i.p. injections of either vehicle (n = 6) or one of the
following anti-inflammatory drugs (AID) minocycline
(n = 5, 100 mg/kg, Sigma) because of its ability to inhibit
microglial activation and attenuation of tumor necrosis
factor signaling, as well as inhibiton of expression of
caspase-1 and caspase-3, cyclooxygenase 2 inhibitor (COX-2
inhibitor) CAY10404 dissolved in DMSO (1 mg/kg, n = 6 or
10 mg/kg, n = 10) (Cayman Chemical, Ann Arbor, MI,
USA), or recombinant interleukin-1 antagonist (rIL-1ra,
100 mg/kg, n = 5) (Amgen Inc., Thousand Oaks, CA,
USA). We were the first to describe in detail the age-
specific pattern of injury that is selective to the CA1 in P14
pups; the dentate hilus and the area CA3 are spared from
SE-induced injury at this very young age [12]. The LPS
injection was used to augment the selective CA1 injury
in the P14 rat pup [14,15] such that even modest
neuroprotection with our AID treatment regimens would
be readily discernible. We also hypothesized that more
than one inflammatory signaling pathway may participate
in mediating acute injury as well as adverse plasticity
leading to epileptogenesis. Thus, in a separate set of
experiments, these P14 pups were injected with different
binary combinations of these AIDs (rIL-1ra + COX-2 in-
hibitor (n = 5); rIL-1ra + minocycline (n = 5); COX-2 in-
hibitor + minocycline (n = 5)). Age-matched vehicle
controls received DMSO or saline. All animals received
diazepam 10 mg/kg i.p. 90 min after pilocarpine injection
to improve survival. Histological analysis using hematoxylin
and eosin was undertaken as described in our previous
papers [12-15].
Following systemic administration of pilocarpine, all rats
showed typical seizure behaviors progressing to stage 3 or
beyond. We found no differences in the latency to seizure
onset in the presence of inflammation induced by LPS or
when any of the anti-inflammatory drugs was used one at
a time (data not shown). When binary combinations were
tried, the combination rIL-1ra + COX-2 inhibitor (CAY
10404, 10 mg/kg) resulted in increased latency to seizure
onset as compared to those given vehicle alone (40.1 ±
9.70 min vs. 17.5 ± 4.08, P <0.01) (Figure 1). However, the
duration of seizure remained similar for all treatments.
Figure 2 shows that only the combination of rIL-1ra +
COX-2 inhibitor resulted in discernible neuroprotection
of CA1 neurons as determined 24 h after SE.
Less than 30% of the rats subjected to SE at P14 de-
velop SRS [12], and treatment with LPS increases that
fraction to about 50% [15]. Our previous work [12] also
showed that by P21, the hippocampal injury produced
by lithium-pilocarpine SE extended beyond the CA1 re-
gion, involving also the hilar interneurons and CA3
neurons. Because >75% of the 3-week-old animals (P21)
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subjected to lithium pilocarpine SE developed SRS and
dense mossy fiber sprouting in our previous studies
[12,13], we deployed rats of this age to evaluate the effi-
cacy of the rIL-1ra + COX-2 inhibitor combination in
preventing epileptogenesis after lithium-pilocarpine SE.
In this set of experiments animals were not primed with
LPS because our goal was not to study injury and
neuroprotection at 24 h, but to observe the rats in the
long term for the development of epilepsy and to evalu-
ate mossy fiber sprouting in the chronically epileptic
animals. Previous work [12,13] has shown that at least
75% of P21 animals develop epilepsy 3 months or longer
after lithium-pilocarpine SE.
Animals were treated with vehicle or one dose of the
combination anti-inflammatory therapy immediately
prior to the administration of pilocarpine. This sequence
of administration was undertaken to ensure that the
agents used in intervention are available even as the in-
flammatory cascade is being set into motion by the SE,
such that a proof of principle as to the validity of the
chosen targets can be established. That can set the back-
ground to explore in the future the window of opportun-
ity for effective intervention after seizures have started.
The only combination used was that involving rIL-1ra
and the COX-2 inhibitor since none of the other
regimens had resulted in discernible neuroprotection in
the earlier set of experiments. A separate group of
animals continued to receive once daily treatment with
the anti-inflammatory cocktail for 10 days following SE.
Four months after SE, animals were implanted with epi-
dural electrodes as described in our other reports and
subjected to a continuous EEG and video monitoring for
a period of 3 weeks for the purpose of acquisition and
analysis of spontaneous recurrent seizures. At the end of
monitoring, animals were euthanized and brains were
processed for the analysis of mossy fiber sprouting using
Timm staining [12,13] and employing a 0–5 scale as pre-
viously described [16].
Monitored at 4 months after SE at the age of 3 weeks, a
single AID treatment consisting of IL-1ra and CAY did
not result in a significant change in the number of rats
developing SRS. Spontaneous seizures were observed in
six of nine vehicle-treated rats, seven of nine rats with
single drug injection, and in six of nine animals with
10-day treatment regimen. However, protracted (10-day)
AID cocktail treatment did reduce seizure frequency
among those animals with spontaneous seizures (Figure 3).
Over 3 weeks of continuous video and EEG monitoring,
vehicle-treated rats exhibited minimal-maximal-median
seizures of 1-18-3; those which received a single injection:
2-13-3; and animals with 10 once-a-day injections: 2-4-2
(*P <0.05 10 days of drug treatment vs. one AID cocktail
treatment or saline treatment).
The analysis of mossy fiber sprouting showed moder-
ate synaptic reorganization in vehicle-treated rats as well
as in animals treated with a single injection of anti-
inflammatory drugs (Figure 4, Timm scores, mean scores
± SEM: 1.81 ± 0.32 and 1.46 ± 0.25, respectively). There
was a statistically significant decrease in mossy fiber
sprouting in the animals treated with anti-inflammatory
drugs for 10 days (Timm score 0.67 ± 0.17; P <0.05 vs.
one AID cocktail treatment or saline treatment).
The disappointing results with sustained AED treatment
of post-SE animals to prevent epileptogenesis have
directed research into other molecular targets. Rather
than modifying neuronal excitability via influencing ion
channel conductance, interest has turned to addressing
pathways that may have a greater effect on plasticity
resulting from seizures. Of those, the neuroinflammation-
related pathways seem to be receiving attention of late [8].
Cyclooxygenase-2 inhibitor celecoxib has been reported
to have a beneficial effect on epileptogenesis following
lithium pilocarpine SE in both mature [17] and developing
[18] rats. However, other investigators found parecoxib,
another COX-2 inhibitor, to be neuroprotective but not
antiepileptogenic [19] in the pilocarpine model of TLE.
However, Holtman et al. [20,21] found that not only was
the COX-2 inhibitor SC-58236 ineffective as an anti-
epileptogenic agent [20] in a rat model of epilepsy after
electrically-induced SE, it actually produced seizure dete-
rioration and increased mortality [21]. Number of diffe-
rences may account for the discrepancy between the
results of Holtman et al. [20,21] and those of ours and
other investigators [17-19]. The model of SE employed in
the Holtman et al. [20,21] studies involved induction of
Figure 1 Status epilepticus (SE) after administration of
lipopolysaccharide (LPS) with or without anti-inflammatory
drugs. Mean (± SEM) of both time to onset (open bar) and total
duration (open + filled bar) after pilocarpine treatment following a
prior injection of LPS or LPS + combination of anti-inflammatory
drugs. The latency to pilocarpine-induced seizure onset in
combination treatment of COX-2 inhibitor plus rIL-1ra with LPS was
significantly delayed as compared to those given vehicle (*P <0.01).
There were no significant changes in total duration of SE among
groups. CAY, COX-2 inhibitor; MINO, minocycline; rIL-1ra =
recombinant interleukin-1 receptor antagonist; VEHS, vehicles.
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SE electrical stimulation of the hippocampus rather than
treatment with lithium-pilocarpine. The SE was much
longer in duration (up to 9 h compared to 60 to 90 min in
the pilocarpine studies, in which the animals received a di-
azepam dose). It is not possible to speculate as to whether
there was some unique toxicity to the specific COX-2 in-
hibitor used in that study. Consistent with the expected
safety and possible benefit of COX-2 inhibition in the
treatment of pilocarpine SE, mice with conditional
ablation of the COX-2 gene in the forebrain enjoyed
diminished mortality and some improvement in memory
performance after pilocarpine-induced SE [22].
Blocking the synthesis of interleukin-1β biosynthesis by
an interleukin converting enzyme antagonist has shown
potential in the model of kindling epileptogenesis [23] as
well as epilepsy induced by kainic acid treatment [24]. The
availability of the human recombinant interleukin-1
receptor antagonist (rIL-1ra) anakinra prompted us to
evaluate its anti-epileptogenic potential, especially since
its transport across the blood–brain barrier [25,26]
appears to be adequate for modifying IL-1β signaling in
the brain. Our experiments showed it to be effective when
combined with the COX-2 selective inhibitor, CAY 10404.
Despite concerns about the potential for fibroblast growth
factor-2 (FGF-2) to increase excitability [27], localized de-
livery of FGF-2 and brain-derived neurotrophic factor
(BDNF) by employing viral vectors has demonstrated po-
tential for anti-epileptogenesis [28,29].
In humans, brain injury from a number of causes such as
SE, traumatic brain injury, hypoxic-ischemic encephalop-
athy, stroke, and so on, give rise to variable incidences of
epilepsy after varying latencies. The classic post-traumatic
epilepsy prevention studies [3] subjected patients to
prolonged treatment with AEDs with significant toxicities
Figure 2 Neuronal injury in hippocampal CA1 subfield after co-administration of anti-inflammatory drugs against LPS + pilocarpine-
induced SE in 2-week-old rats. Treatment with a single anti-inflammatory compound did not diminish the amount of CA1 hippocampal
damage as compared to vehicle (left column). A combination treatment of rIL-1ra + CAY resulted in significant reduction of injured neurons
which was not seen with any other combination (right column). Outset shows high magnification of eosinophilic neurons with pyknotic nuclei
and irregular cell bodies that were counted as injured CA1 cells in the graph. Bars represent mean ± SEM. Quantification shows significant
attenuation of neuronal injury resulted from combined administration of rIL-1ra + CAY administered prior to the onset of status (*P <0.05). CAY,
COX-2 inhibitor (10 mg/kg); MINO, minocycline; naïve, age-matched normal rat (no seizures, no treatment); rIL-1ra, recombinant interleukin-1
receptor antagonist; VEH, vehicle. Scale bar is 50 μm.
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and side effects, and still failed to prevent the development
of epilepsy. Our results highlight that both limited
neuroprotection and a modicum of anti-epiletogenic dis-
ease modification can be achieved by targeting inflamma-
tion. However, the translationally important message is
that while evidence exists supporting the role of many indi-
vidual inflammatory pathways, only a specific combination
therapy provided discernible benefits. Further, the AID
cocktail treatment protocol involved a limited duration,
unlike the chronic AED regimens that have been tried in
humans as well as animal models. The importance of our
findings for clinical translation are that our intuition-
driven empiric AID cocktail design leverages elucidated
mechanisms involving specific pathways while enabling: (1)
treatment with drug classes that have already been
evaluated for safety and approved for human use; (2) short
duration treatment with drug classes that are already in
use for chronic conditions; and (3) does not involve intro-
duction of viral vectors into the CNS. It remains to be
shown if the doses and duration of the regimen can be
optimized for greater efficacy, and if such treatment
may also modify the evolution of epilepsy-associated co-
morbidities that seem to impact on the quality of life of
patients even more than seizure frequency.
Figure 3 Protracted anti-inflammatory drug treatment reduced
the frequency of spontaneous recurrent seizures (SRS) among
epileptic animals. Bar graphs represent the average number of
seizures observed. Over 3 weeks of continuous video and EEG
monitoring, vehicle-treated animals (VEHS) presented an average of
2.9 ± 0.6 seizures per week, while those treated with a single
injection of anti-inflammatory drug (AID) did not show significant
reduction in seizure frequency and exhibited an average of 2.5 ± 0.4
seizures per week (P >0.5). Animals treated with daily injections of
AID for 10 consecutive days showed a marked decrease in SRS
frequency (*P <0.05 10 days of drug treatment vs. two other groups,
n = 8).
Figure 4 Timm staining showing mossy fiber sprouting in supragranular region of the dentate gyrus of saline-treated and AID-treated
animals. (A) Vehicle treated. (B) The second group of animals was injected with AID for 1 day. (C) The third group received AID treatment for 10
consecutive days after induction of status epilepticus. Four months after SE, brains were harvested and processed for Timm staining. (D)
Protracted AID (10-days) reduced mossy fiber sprouting as observed using Timm staining. Analysis of mossy fiber sprouting showed synaptic
reorganization in vehicle-treated rats as well as in animals treated with a single injection of anti-inflammatory drugs (Timm scores 1.81 ± 0.32 and
1.46 ± 0.25, respectively). There was a statistically significant decrease in mossy fiber sprouting in the animals treated with anti-inflammatory
drugs for 10 days (Timm score 0.67 ± 0.17); (P <0.05 vs. each of two other groups). Scale bar, 100 um.
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